Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Deep invasive endometriosis (DIE) includes lesions of the rectosigmoid. Theses lesions are associated with painful symptoms that can alter quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative procedure using a high-intensity ultrasound probe to induce tissue devitalization using acoustic cavitation and thermal ablation. Focal One® is a transrectal HIFU device, which is validated to treat prostatic cancer.
The primary objective of this clinical trial is to evaluate the ability of the Focal One® HIFU device to detect and target posterior DIE lesions with intestinal involvement. The secondary objectives are to perform a HIFU lesion, to evaluate morphological modifications of the nodule in post-therapeutic imaging scans, to assess evolution of gynecological symptoms, intestinal symptoms, and patients' quality of life after treatment by HIFU and to collect safety data.
20 Subjects with deep invasive endometriosis (DIE) will receive the HIFU treatment with Focal One® device.
Subjects harboring an isolated recto-sigmoid DIE lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:
Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and at 1 and 6 months after HIFU procedure. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIFU (Focal One®) Treatment | Experimental | Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:
Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HIFU (Focal One®) | Device | Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae. |
| Measure | Description | Time Frame |
|---|---|---|
| Targeting of the endometriosic lesion | The main criterion of evaluation will lie on the targeting of the Endometriosic lesion with the Focal One® probe. Measure of the volume of the Endometriosic lesion to treat: targeted volume (estimation from the measures of the length, the height and the width of the nodule). | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Anatomical position of the Focal One probe | The objective is to evaluate the position of the probe within the rectum before HIFU treatment. | Day 1 |
| Effect of HIFU treatment on endometriosic lesion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
deep invasive endometriosis (DIE)
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gil DUBERNARD, MD PhD | Hôpital de la Croix Rousse Service de Gynécologie-Obstétrique, Hospices Civils de Lyon, 103, Grande rue de la Croix Rousse 69 004 Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital de la Croix Rousse | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Dec 3, 2021 | |
| Reset | Feb 18, 2022 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 3, 2021 | Feb 18, 2022 |
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
Ratio calculation between targeted volume and treated volume and Evaluation of HIFU on symptomatology
| Day 1 |
| Safety of the procedure: assessment of complications during the procedure attributable to the technique | Complications during HIFU treatment attributable to the HIFU energy deposit or the Focal One are described here. | Day 1 |
| Assessment of Adverse Events during the 6 months follow-up attributable to the technique | Complications post HIFU treatment. | 6 months |
| Medical Outcome assessment (Study Short Form-36) | self-administrated questionnaire: French version of the 36-item Short Form Survey (SF-36) | 6 months |
| endometriosis health profile assessment | self-administrated questionnaire: endometriosis health profile (EHP-5) | 6 months |
| Urinary symptom profile assessment | self-administrated questionnaire: urinary symptom profile (USP) | 6 months |
| Sexual function assessment | self-administrated questionnaire: Female Sexual Function Index (FSFI) | 6 months |
| Constipation assessment | self-administrated questionnaire: Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) | 6 months |
| Anal continence assessment | self-administrated questionnaire: Wexner score of anal continence | 6 months |
| D000091662 | Genital Diseases |